Literature DB >> 8331552

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).

Y Shibouta1, Y Inada, M Ojima, T Wada, M Noda, T Sanada, K Kubo, Y Kohara, T Naka, K Nishikawa.   

Abstract

The angiotensin II (AII) antagonistic action of 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl-1H-benzi mid azole-7 - carboxylic acid (CV-11974) was examined in in vitro assay systems, including AII receptor binding assay using membrane fractions of bovine adrenal cortex or rabbit aorta and AII-induced contraction assay using rabbit aortic strips, and CV-11974 and its prodrug, (+/-)1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), were examined in an in vivo system of AII-induced pressor response in conscious rats. DuP 753 or EXP3174 (the main active metabolite of DuP 753) was used as the reference compound. CV-11974 inhibited the binding of [125I] AII to the bovine adrenal cortical membrane and rabbit aortic membrane with IC50 values of 1.12 x 10(-7) and 2.86 x 10(-8) M, respectively. Similar results were obtained with EXP3174. CV-11974 interacted with AII in these membrane fractions with subtype 1 receptor in a competitive manner. CV-11974 at 10(-5) M did not affect the binding of [125I]AII to subtype 2 (AT2) receptor in bovine cerebellum. CV-11974 selectively inhibited the AII-induced contraction of rabbit aortic strips in a noncompetitive manner (pD' 2, 9.97); it had no effects on the contraction induced by norepinephrine, KCl, serotonin, prostaglandin F2 alpha or endothelin. EXP3174 showed a pD'2 value of 8.95 for the AII-induced contraction. CV-11974 given intravenously and TCV-116 given orally inhibited the AII-induced pressor response in rats with ID50 values of 0.033 mg/kg and 0.069 mg/kg, respectively. These effects of CV-11974 and TCV-116 were 12 and 48 times more potent than those of EXP3174 and DuP 753, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8331552

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

1.  Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.

Authors:  Chantal Csajka; Thierry Buclin; Karin Fattinger; Hans R Brunner; Jérôme Biollaz
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Evidence for a functional cardiac interaction between losartan and angiotensin-(1-7) receptors revealed by orthostatic tilting test in rats.

Authors:  Marina Matos de Moura; Robson Augusto Sousa dos Santos; Marco Antônio Peliky Fontes
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

3.  Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole.

Authors:  S Arima; Y Endo; H Yaoita; K Omata; S Ogawa; K Tsunoda; M Abe; K Takeuchi; K Abe; S Ito
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 4.  Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.

Authors:  C Csajka; T Buclin; H R Brunner; J Biollaz
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

5.  Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors.

Authors:  P M Vanderheyden; I Verheijen; F L Fierens; J P DeBacker; G Vauquelin
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

6.  Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis.

Authors:  M Pfister; F Schaedeli; F J Frey; D E Uehlinger
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

7.  Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.

Authors:  P M Vanderheyden; F L Fierens; J P De Backer; N Fraeyman; G Vauquelin
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

8.  CV-11974, angiotensin II type I receptor antagonist, reduces the severity of indomethacin-induced rat enteritis.

Authors:  Toshimitsu Okuda; Norimasa Yoshida; Tomohisa Takagi; Osamu Handa; Satoshi Kokura; Hiroshi Ichikawa; Yuji Naito; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

Review 9.  Candesartan cilexetil. A review of its use in essential hypertension.

Authors:  K J McClellan; K L Goa
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

10.  Angiotensin II stimulates both aldosterone secretion and DNA synthesis via type 1 but not type 2 receptors in bovine adrenocortical cells.

Authors:  A Tanabe; M Naruse; K Arai; K Naruse; T Yoshimoto; T Seki; T Imaki; M Kobayashi; H Miyazaki; H Demura
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.